Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - lamivudine - film coated tablets - lamivudine 150 mg - lamivudine - epivir is indicated as part of antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infected adults and children.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - lamivudine - film coated tablets - lamivudine 300 mg - lamivudine - epivir is indicated as part of antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infected adults and children. 28/10/2018 בקשה לשינוי משטר מינון

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - lamivudine - film coated tablets - lamivudine 150 mg - lamivudine - lamivudine - epivir is indicated as part of antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infected adults and children. 25/10/2018 בקשה לשינוי משטר מינון

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viiv healthcare uk ltd - lamivudine - tablet - 150mg

United States - English - NLM (National Library of Medicine)

viiv healthcare company - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 150 mg - epivir is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (hiv‑1) infection. limitations of use: epivir is contraindicated in patients with a previous hypersensitivity reaction to lamivudine. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to epivir during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data) . the apr uses the macdp as the u.s. reference population for birth defects in the general population. the macdp evaluates women and infants from a limited geographic area and does not include outcome

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - lamivudine - film coated tablets - lamivudine 300 mg - lamivudine - lamivudine - epivir is indicated as part of antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infected adults and children. 28/10/2018 בקשה לשינוי משטר מינון

United States - English - NLM (National Library of Medicine)

rebel distributors corp - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 150 mg - epivir is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. limitation of use: the dosage of this product is for hiv-1 and not for hbv. epivir tablets and oral solution are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., anaphylaxis) to any of the components of the products. pregnancy category c. there are no adequate and well-controlled studies of epivir in pregnant women. animal reproduction studies in rats and rabbits revealed no evidence of teratogenicity. increased early embryolethality occurred in rabbits at exposure levels similar to those in humans. epivir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. lamivudine pharmacokinetics were studied in pregnant women during 2 clinical studies conducted in south africa. the study assessed pharmacokinetics in: 16 women at 36 weeks gestation using 150 

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 150 mg - epivir is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. limitation of use: the dosage of this product is for hiv-1 and not for hbv. epivir tablets and oral solution are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., anaphylaxis) to any of the components of the products. pregnancy category c. there are no adequate and well-controlled studies of epivir in pregnant women. animal reproduction studies in rats and rabbits revealed no evidence of teratogenicity. increased early embryolethality occurred in rabbits at exposure levels similar to those in humans. epivir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. lamivudine pharmacokinetics were studied in pregnant women during 2 clinical studies conducted in south africa. the study assessed pharmacokinetics in: 16 women at 36 weeks gestation using 150 

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 150 mg - epivir is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. limitation of use: the dosage of this product is for hiv-1 and not for hbv. epivir tablets and oral solution are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., anaphylaxis) to any of the components of the products. pregnancy category c. there are no adequate and well-controlled studies of epivir in pregnant women. animal reproduction studies in rats and rabbits revealed no evidence of teratogenicity. increased early embryolethality occurred in rabbits at exposure levels similar to those in humans. epivir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. lamivudine pharmacokinetics were studied in pregnant women during 2 clinical studies conducted in south africa. the study assessed pharmacokinetics in: 16 women at 36 weeks gestation using 150 

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

mylan laboraories limited - tenofovir disoproxil fumarate, lamivudine,efavirenz - tablets film-coated - 300mg+ 300mg+ 400mg